 |
|
Clinical Trial Results - Progress in Cancer Care
These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.
The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.
6. Thalidomide Effective in Multiple Myeloma
(Posted: 03/15/2006, Updated: 09/16/2008) - In the March 9, 2006, issue of the New England Journal of Medicine, researchers report superior event-free and complete response rates when the drug thalidomide was used before and during primary therapy for multiple myeloma. Longer follow-up showed a survival benefit for some patients, as well.
7. Bortezomib Approved for First-Line Treatment of Multiple Myeloma
(Posted: 09/11/2008) - The targeted drug bortezomib, when added to standard therapy (melphalan and prednisone), significantly improves time to progression and overall survival in patients with newly diagnosed multiple myeloma, according to the August 28, 2008, New England journal of Medicine.
8. Denosumab May Help Prevent Bone Loss Related to Use of Aromatase Inhibitors
(Posted: 09/11/2008) - Treatment with the experimental drug denosumab increased bone density in postmenopausal women taking aromatase inhibitors to prevent a recurrence of breast cancer, according to a report published online August 25, 2008, by the Journal of Clinical Oncology.
9. Eliminating a Common Bacterium Reduces Risk of Second Gastric Cancer
(Posted: 09/02/2008) - When the bacterium Helicobacter pylori is eliminated in patients who are treated for early stage gastric cancer, the risk of developing a second gastric cancer decreases by two-thirds, according to the Aug. 2, 2008, issue of The Lancet.
10. Follicular Lymphoma Treatment Better With Rituximab
(Posted: 05/15/2005, Updated: 08/18/2008) - In patients with newly diagnosed follicular lymphoma, the addition of rituximab (Rituxan®) to the standard chemotherapy regimen CVP dramatically delayed the progression of disease, produced higher response rates that lasted longer, and extended survival compared to treatment with CVP alone, according to the July 28, 2008, Journal of Clinical Oncology.
< Previous 1 2 3 4 5 Next >
|
|
|
